Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. De Giorgi U, et al. Among authors: shen q. Eur J Cancer. 2021 Dec;159:237-246. doi: 10.1016/j.ejca.2021.10.015. Epub 2021 Nov 14. Eur J Cancer. 2021. PMID: 34784577 Free article. Clinical Trial.
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND. Freedland SJ, et al. Among authors: shen q. BMJ Open. 2021 Aug 12;11(8):e046588. doi: 10.1136/bmjopen-2020-046588. BMJ Open. 2021. PMID: 34385241 Free PMC article. Clinical Trial.
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Penson DF, et al. Among authors: shen q. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363-365. doi: 10.1038/s41391-021-00465-7. Epub 2021 Oct 7. Prostate Cancer Prostatic Dis. 2022. PMID: 34621011 Free PMC article. Clinical Trial.
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Penson DF, et al. Among authors: shen q. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597. doi: 10.1038/s41391-021-00477-3. Prostate Cancer Prostatic Dis. 2022. PMID: 34848822 Free PMC article. No abstract available.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Hussain M, et al. Among authors: shen q. Future Oncol. 2023 Sep;19(29):1953-1960. doi: 10.2217/fon-2023-0135. Epub 2023 Aug 10. Future Oncol. 2023. PMID: 37585665 Free article. Review.
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
Adkins DR, Lin JC, Sacco A, Ley J, Oppelt P, Vanchenko V, Komashko N, Yen CJ, Wise-Draper T, Lopez-Picazo Gonzalez J, Radulovic S, Shen Q, Thurm H, Martini JF, Hoffman J, Huang X, Melichar B, Tahara M. Adkins DR, et al. Among authors: shen q. Oral Oncol. 2021 Apr;115:105192. doi: 10.1016/j.oraloncology.2021.105192. Epub 2021 Feb 8. Oral Oncol. 2021. PMID: 33571736 Clinical Trial.
Prostate cancer stem cells: an updated mini-review.
Zhou K, Lu H, Zhang J, Shen Q, Liu P, Xu Q, Yang C, Mao L. Zhou K, et al. Among authors: shen q. J Cancer. 2024 Oct 28;15(20):6570-6576. doi: 10.7150/jca.100604. eCollection 2024. J Cancer. 2024. PMID: 39668824 Free PMC article. Review.
6,371 results